Navigation Links
Baseline characteristics of children with mild persistent asthma predict response to ICS
Date:5/22/2012

ATS 2012, SAN FRANCISCO A further analysis of a previously published National Heart, Lung, and Blood Institute (NHLBI) funded study of children with mild persistent asthma reports the relative benefits of inhaled corticosteroid (ICS) treatment varies among children with differing demographic and clinical characteristics.

"We performed post-hoc data analysis on 288 children enrolled in the TReating Children to Prevent Exacerbations of Asthma (TREXA) study performed by the NHLBI funded Childhood Asthma Research and Education (CARE) Network," said Lynn Gerald, PhD, MSPH, professor in the Department of Health Promotion Sciences and associate dean of research in the College of Public Health at the University of Arizona. "Our findings suggest that all children with mild persistent asthma benefit from ICS treatment, but some groups benefit more than others."

The TREXA trial compared four ICS treatment strategies: daily treatment (daily), daily treatment plus symptom-targeted treatment (combined), symptom-targeted only treatment (rescue), and placebo. Daily treatment, but not combined or rescue treatment, reduced the time to first exacerbation compared with placebo, and all three strategies reduced treatment failures. Time to treatment failure was defined as time to an oral corticosteroid-requiring exacerbation and treatment failure was defined as experiencing two or more oral corticosteroid-requiring exacerbations.

In post-hoc subgroup analyses using either time to first exacerbation or time to treatment failure as an outcome, children in the daily and combined groups who were younger (6-11 yrs versus 12-17 years), were non-Hispanic, had eczema, were skin test positive, and who had IgE levels >185K/uL experienced treatment benefit as compared to those assigned to placebo. Among children assigned to the rescue group, the results were similar to those above when using time to treatment failure as an outcome; however, when using time to first exacerbation as an outcome, only those with eczema, high IgE levels, and less than perfect asthma control during the run-in period were demonstrated to benefit when compared to placebo.

"Our study indicates that some groups of children with mild persistent asthma have greater exacerbation risk than others and therefore have more to gain from ICS treatment for reducing this risk," said Dr. Gerald. "These findings need to be validated in future studies."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Baseline PSA predicts risk of death from prostate cancer
2. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
3. Does baseline concussion testing really reduce risks to athletes?
4. Validity of Baseline Concussion Tests Questioned
5. Concussion baseline important for accurate future assessment in at-risk youth athletes
6. Researchers find that sociodemographic characteristics are related to a patients willingness to participate in cancer screenings
7. Researchers report no difference in breast cancer characteristics after oophorectomy
8. Thesis investigates characteristics of society using sports activities as research tool
9. Why do risks with human characteristics make powerful consumers feel lucky?
10. New study helps clarify symptoms and characteristics of acid reflux in neonates
11. Pain characteristics suggest higher benefit from gallbladder surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network and the ... D’Achille Center for Women’s Behavioral Health at West Penn Hospital , a unique ... women suffering from pregnancy-related depression. Construction of the Center is underway with a ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, ... in KLAS category winner, has named Daniel P. Bullington as chief technology officer. ... technology platform and product offerings,” says Justin Neece, president. “Daniel is an excellent ...
(Date:5/23/2017)... ... ... London, May 23, 2017: Walter Schindler, the Founder and Managing Partner of ... and Contributor to a weeklong series of classes, meetings, field trips and special events ... Schindler and SAIL Capital have received an increasing number of awards ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
(Date:5/3/2017)... May 3, 2017 A Catheterization Laboratory ... or healthcare facility. Commonly referred to as cath ... with diagnostic imaging technology to give physicians visual ... In these spaces, a team of physicians perform ... percutaneous coronary intervention, congenital heart defect closure, stenotic ...
(Date:5/3/2017)... , May 3, 2017  Getinge, a leading ... to quality enhancement and cost efficiency within healthcare ... study of contemporary practice demonstrating that intra-aortic balloon ... for critically ill patients. The single-center, retrospective, observational ... large volume MEGA ® 50cc intra-aortic balloon ...
Breaking Medicine Technology: